Madam Speaker, it is surprising that in the middle of a health pandemic, members opposite are not invested in vaccinations and the state of where we are as a country. That is very concerning.
Part of the groundwork I am laying is connected to the important work of the microbiology lab, so I absolutely will continue. However, this is important information for all Canadians.
Indigenous communities and the territories have made excellent strides in increasing vaccination coverage. To date, more than three-quarters of adults in the three territories have received at least one dose of COVID‑19 vaccine and 66% have received two doses.
A first dose of COVID‑19 vaccine provides us with primary protection, but for maximum protection, we need a second immunity-boosting dose.
The Government of Canada expects that by the end of the next two quarters, Canada will have received in Q2, end of June, more than 40 million cumulative doses and by Q3, end of September, more than 100 million cumulative doses. Looking ahead, we expect weekly shipments of 2.4 million Pfizer doses per week in June and close to 2.3 million doses weekly in July. Regarding Moderna, we are actively working with our colleagues at Public Service and Procurement Canada and the manufacturers to determine the delivery schedule and shipment sizes for June.
Last month, my hon. colleague, the Minister of Public Services and Procurement, announced that Canada had secured COVID‑19 vaccines from Pfizer for 2022 and 2023, with options—